Data Sheet (Cat.No.T24444)

TargetMol

Medifoxamine

Chemical Properties



CAS No. : 32359-34-5

Formula: C16H19NO2

Molecular Weight: 257.33

Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Medifoxamine (LG 152) is a selective non-monoamine oxidase inhibitor that exhibits antidepressant activity through inhibition of 5 HT reuptake.Medifoxamine preferentially inhibits dopamine reuptake.
Targets(IC50)	Dopamine Receptor,Monoamine Oxidase
In vivo	Medifoxamine (200, 500, 750, and 1000 mg; oral) was well tolerated and exhibited a first-order linear pharmacokinetic profile. It underwent rapid absorption and peak plasma concentrations were achieved about 1.0 h after administration. Thereafter the elimination profile was biphasic with a mean terminal half-life less than 3 hours. We found a linear relationship (r = 0.80) between administered dose and AUC values for the four doses. High values were obtained for the apparent volumes of distribution and the plasma clearance.[4]

Solubility Information

Solubility	DMSO: 90 mg/mL (349.75 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (12.82 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.8861 mL	19.4303 mL	38.8606 mL
5 mM	0.7772 mL	3.8861 mL	7.7721 mL
10 mM	0.3886 mL	1.943 mL	3.8861 mL
50 mM	0.0777 mL	0.3886 mL	0.7772 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Saleh S, et al. Ocular hypotensive effects of medifoxamine. Br J Clin Pharmacol. 1992;34(3):269-271.
Lehert P, et al. New statistical proposals to evaluate the benefit/risk ratio of long-term treatment of depression: application to a one-year double-blind study comparing medifoxamine with fluoxetine. Clin Drug Investig. 1998; 15(4):285-295.
Saleh S, et al. Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans. Br J Clin Pharmacol. 1990;30(4):621-624.
Saleh S, et al. Medifoxamine: oral tolerance and pharmacokinetic study in healthy human volunteers. Eur J Clin Pharmacol. 1990;39(2):169-171.